Our Science

In vitro assays showcased our lead constructs' superiority over standard CAR-T cells, while in vivo studies confirmed their effectiveness in achieving enhanced long-term tumor clearance compared to conventional CAR-T therapies.

Insights

% lysis of target cells by control and CD19-CAP-T cells incubated with indicated target cells at a 5:1 ratio.

IFN gamma secretion evaluated by ELISA from supernatants of control and CD19-CAP-T cells incubated with the indicated target cells at a 1:1 ratio for 16 hrs.

Proliferation of control and CD19-CAP-T cells.

Our preclinical evidence strongly substantiates the promise of CAP-T™ as a first-in-class therapy, signifying a significant leap towards more effective treatments in the near future.